

SEREBRAL PALSİDE NÖROŞİRÜRJİKAL YAKLAŞIMLAR

6. BÖLÜM

Erhan ARSLAN¹

Nöroşirürjiyenler uzun yıllardır üst motor nöron problemlerini tedavi etmekte önemli rol oynamışlardır. Üst motor nöron problemlerinin başlıcaları kaslarda hiperaktiviteye bağlı spastisite veya distonilerdir. Spastisite tedavisinde sinir lezyon işlemleri ilk olarak yirminci yüzyıl başlarında kullanılmaya başlanmıştır. Giderek modifikasyonlar ve yenilikler ile günümüze kadar bu tedaviler gelmiştir (1). İntratekal infüzyon aletleri yerleştirme ve derin beyin sitümülâtörlerindeki gelişmelerden dolayı nöroşirürjiyenlerin rolü, serebral palsi cerrahisinde giderek artarak devam etmektedir. Bu bölümde spastisite cerrahisinde yapılan sinir lezyon cerrahileri (selektif periferik nörotomi, selektif dorsal rizotomi, dorsal root giriş zone lezyonları) ve distoni tedavisi için derin beyin sitimulasyonu işlemleri ve intratekal baklofen uygulaması anlatılacaktır. Tüm bu cerrahi tedaviler multidisipliner ekip çalışması sonunda uygun hastalara uygulanmaktadır (2).

Spastisite kas sertliği, ağrı, rahatsızlık ve azalmış fonksiyona sebep olur. Serebral palsili (SP) hastaların kasları daha küçük, zayıf ve farklı bir histolojiye sahiptirler. Bunların yanında, spastisite daha kısa kaslara, kontraktür gelişimine, uzun kemiklerde torsiyona ve eklemlerde dejenerasyona da sebep olur. Çocuk hastalarda sıklıkla çok seviye ortopedik cerrahi girişime ihtiyaç duyulur. Yumuşak doku gevşetme, femoral osteotomiler ve kalça rekonstrüksiyonları bu cerrahi girişimlerden bazılarıdır (3). Spastisite istemli hareketleri zora sokarak büyümeyle birlikte deformitelere sebep olabilir. Spastisite azaltıldığında

¹ Doç. Dr. Karadeniz Teknik Üniversitesi Tıp Fakültesi, Beyin ve Sinir Cerrahisi AD

KAYNAKLAR

1. Boop FA. Evolution of the neurosurgical management of spasticity. *J Child Neurol* 2001;16(1):54–7.
2. Madsen PJ, Isaac Chen HC, Lang SS. Neurosurgical Approaches. *Phys Med Rehabil Clin N Am*. 2018 Aug;29(3):553-565. doi: 10.1016/j.pmr.2018.04.002.
3. Aquilina K, Graham D, Wimalasundera N. Selective dorsal rhizotomy: the re-emergence of an old technique. *Arch Dis Child* 2015;100:798–802.
4. Thomas SP, Addison AP, Curry DJ. Surgical Tone Reduction in Cerebral Palsy. *Phys Med Rehabil Clin N Am*. 2020 Feb;31(1):91-105. doi:10.1016/j.pmr.2019.09.008.
6. Penn R, Kroin J. Continuous intrathecal baclofen for severe spasticity. *Lancet* 1985;326:125–7.
7. Butler C, Campbell S. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy. *Dev Med Child Neurol* 2000;42:634–45.
8. Ivanhoe CB, Tilton AH, Francisco GE. Intrathecal baclofen therapy for spastic hypertonia. *Phys Med Rehabil Clin N Am* 2001;12(4):923–38.
9. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. *J Child Neurol* 1996;11(S1):S29–35.
10. Pruszczynski B, Sees J, Hulbert R, et al. The effect of continuous intrathecal baclofen therapy on ambulatory children with cerebral palsy. *J Pediatr Orthop B* 2018;27(3):214–20.
11. Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. *Arch Phys Med Rehabil* 1996;77:461.
12. Francisco GE. The effect of intrathecal baclofen therapy on walking speed of individuals with post-stroke hemiplegia. *Arch Phys Med Rehabil* 2000;81:1295.
13. Gray N, Morton RE, Brimlow K, et al. Goals and outcomes for non-ambulant children receiving continuous infusion of intrathecal baclofen. *Eur J Paediatr Neurol* 2012;16:443–8.
14. Motta F, Stignani C, Antonello CE. The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases.
15. Motta F, Stignani C, Antonello CE. Effect of intrathecal baclofen on dystonia in children with cerebral palsy and the use of functional scales. *J Pediatr Orthop* 2008;28:213–7.
16. Motta F, Antonello CE, Stignani C. Upper limbs function after intrathecal baclofen therapy in children with secondary dystonia. *J Pediatr Orthop* 2009;29:817–21.
17. Hidalgo ET, Orillac C, Hersh A, et al. Intrathecal baclofen therapy for the treatment of spasticity in Sjogren-Larsson syndrome. *J Child Neurol* 2017;32:100–3.
18. Brochard S, Remy-Neris O, Filipetti P, et al. Intrathecal baclofen infusion for ambulant children with cerebral palsy. *Pediatr Neurol* 2009;20:265–70.
19. Bottanelli M, Rubini G, Venturelli V, et al. Weight and height gain after intrathecal baclofen pump implantation in children with spastic tetraparesis. *Dev Med Child Neurol* 2004;46(11):788–9.
20. Buonaguro V, Scelsa B, Curci D, et al. Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. *Pediatr Neurol* 2005;33(2):110–3.

21. Roberts A. Surgical management of spasticity. *J Child Orthop* 2013;7:389–94.
22. Armstrong RW, Steinbok P, Cochrane DD, et al. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. *J Neurosurg* 1997;87(3):409–14.
23. Albright AL, Awaad Y, Muhonen M, et al. Performance and complications associated with the synchroMed 10-ml infusion pump for intrathecal baclofen administration in children. *J Neurosurg* 2004;101(S1):64–8.
24. Lam SK, Mayer RR, Vedantam A, et al. Readmission and complications within 30 days after intrathecal baclofen pump placement. *Dev Med Child Neurol* 2018;60(10):1038–44.
25. Burn SC, Zeller R, Drake JM. Do baclofen pumps influence the development of scoliosis in children? *J Neurosurg Pediatr* 2010;5(2):195–9.
26. Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic quadriplegia after insertion of an intrathecal baclofen pump. *Spine* 2007;32(34):2745–50.
27. Sansone JM, Mann D, Noonan K, et al. Rapid progression of scoliosis following insertion of intrathecal baclofen pump. *J Pediatr Orthop* 2006;26(1):125–8.
28. Gooch JL, Oberg WA, Grams B, et al. Care provider assessment of intrathecal baclofen in children. *Dev Med Child Neurol* 2004;46(8):548–52.
29. Shilt JS, Lai LP, Cabrera MN, et al. The impact of intrathecal baclofen on the natural history of scoliosis in cerebral palsy. *J Pediatr Orthop* 2008;28(6):684–7.
30. Walter M, Altermatt S, Furrer C, et al. Intrathecal baclofen therapy in children with severe spasticity: outcome and complications. *Dev Neurorehabil* 2014;17:368–74.
31. Murphy NA, Irwin MC, Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. *Arch Phys Med Rehabil* 2002;83:1721–5.
32. Overgard TM, Kjaersgaard-Hansen L, Soe M, et al. Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. *Dan Med J* 2015;62:A4999.
33. Sindou M, Georgoulis G, Mertens P. Lesioning surgery for spasticity. In: Youmans and Winn RH neurological surgery. 7th edition. Philadelphia: Elsevier; 2017.p. 716–28.
34. Lorenz F. Über chirurgische Behandlung der angeborenen spastischen Gliedstarre. *Wien Klin Wochenschr* 1887;21:25–7.
35. Stoffel A. The treatment of spastic contractures. *American Journal of Orthopaedic Surgery* 1913;2–10(4):611–44.
36. Sitthinamsuwan B, Nunta-Aree S. Ablative neurosurgery for movement disorders related to cerebral palsy. *J Neurosurg Sci* 2015;59(4):393–404.
37. Sindou MP, Simon F, Mertens P, et al. Selective peripheral neurotomy (SPN) for spasticity in childhood. *Childs Nerv Syst* 2007;23(9):957–70.
38. Lazorthes Y, Sol J-C, Sallerin B, et al. The surgical management of spasticity. *Eur J Neurol* 2002;9(s1):35–41.
39. Foerster O. On the indications and results of the excision of posterior spinal nerve roots in men. *Surg Gynecol Obstet* 1913;16(5):463–74.
40. Health Quality Ontario. Lumbosacral dorsal rhizotomy for spastic cerebral palsy: a health technology assessment. *Ont Health Technol Assess Ser* 2017;17(10):1–

- 186.
41. McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: metaanalysis of three randomized controlled trials. *Dev Med Child Neurol* 2002;44(1):17–25.
 42. Park TS, Liu JL, Edwards C, et al. Functional Outcomes of Childhood Selective Dorsal Rhizotomy 20 to 28 Years Later. *Cureus* 2017;9(5):e1256.
 43. Dudley RWR, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. *J Neurosurg Pediatr* 2013;12(2):142–50.
 44. Ailon T, Beauchamp R, Miller S, et al. Long-term outcome after selective dorsal rhizotomy in children with spastic cerebral palsy. *Childs Nerv Syst* 2015;31(3):415–23.
 45. Nordmark E, Josenby AL, Lagergren J, et al. Long-term outcomes five years after selective dorsal rhizotomy. *BMC Pediatr* 2008;8:54.
 46. Josenby AL, Wagner P, Jarnlo G-B, et al. Motor function after selective dorsal rhizotomy: a 10-year practice-based follow-up study. *Dev Med Child Neurol* 2012;54(5):429–35.
 47. Steinbok P. Selection of treatment modalities in children with spastic cerebral palsy. *Neurosurg Focus* 2006;21(2):e4.
 48. Rumberg F, Bakir MS, Taylor WR, et al. The effects of selective dorsal rhizotomy on balance and symmetry of gait in children with cerebral palsy. *PLoS One* 2016;11(4):e0152930.
 49. Bolster EAM, van Schie PEM, Becher JG, et al. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. *Dev Med Child Neurol* 2013;55(7):610–6.
 50. Craft S, Park TS, White DA, et al. Changes in cognitive performance in children with spastic diplegic cerebral palsy following selective dorsal rhizotomy. *Pediatr Neurosurg* 1995;23(2):68–74 [discussion: 75].
 51. Gigante P, McDowell MM, Bruce SS, et al. Reduction in upper-extremity tone after lumbar selective dorsal rhizotomy in children with spastic cerebral palsy. *J Neurosurg Pediatr* 2013;12(6):588–94.
 52. Grunt S, Fiegggen AG, Vermeulen RJ, et al. Selection criteria for selective dorsal rhizotomy in children with spastic cerebral palsy: a systematic review of the literature. *Dev Med Child Neurol* 2014;56(4):302–12.
 53. Funk JF, Panthen A, Bakir MS, et al. Predictors for the benefit of selective dorsal rhizotomy. *Res Dev Disabil* 2015;37:127–34.
 54. Reynolds MR, Ray WZ, Strom RG, et al. Clinical outcomes after selective dorsal rhizotomy in an adult population. *World Neurosurg* 2011;75(1):138–44.
 55. Kan P, Gooch J, Amini A, et al. Surgical treatment of spasticity in children: comparison of selective dorsal rhizotomy and intrathecal baclofen pump implantation. *Childs Nerv Syst* 2008;24(2):239–43.
 56. Ingale H, Ughratdar I, Muquit S, et al. Selective dorsal rhizotomy as an alternative to intrathecal baclofen pump replacement in GMFCS grades 4 and 5 children. *Childs Nerv Syst* 2016;32(2):321–5.
 57. D'Aquino D, Moussa AA, Ammar A, et al. Selective dorsal rhizotomy for the tre-

- atment of severe spastic cerebral palsy: efficacy and therapeutic durability in GMFCS grade IV and V children. *Acta Neurochir (Wien)* 2018;160(4):811–21.
58. Steinbok P. Selective dorsal rhizotomy for spastic cerebral palsy: a review. *Childs Nerv Syst* 2007;23(9):981–90.
 59. Mertens P, Sindou M. Microsurgical drezotomy for the treatment of spasticity of the lower limbs. *Neurochirurgie* 1998;44(3):209–18.
 60. Sindou M, Quoex C, Baleyrier C. Fiber organization at the posterior spinal cord rootlet junction in man. *J Comp Neurol* 1974;153(1):15–26.
 61. Sitthinamsuwan B, Phonwijit L, Khampalikit I, et al. Comparison of efficacy between dorsal root entry zone lesioning and selective dorsal rhizotomy for spasticity of cerebral origin. *Acta Neurochir (Wien)* 2017;159(12):2421–30.
 62. Sindou M. Microsurgical DREZotomy (MDT) for pain, spasticity, and hyperactive bladder: a 20-year experience. *Acta Neurochir (Wien)* 1995;137(1–2):1–5.
 63. Konrad P. Dorsal root entry zone lesion, midline myelotomy and anterolateral cordotomy. *Neurosurg Clin N Am* 2014;25(4):699–722.